16 patents
Utility
Antibodies Targeting HER2 and CD3 and Uses Thereof
21 Dec 23
Provided herein are antibodies that selectively bind to HER2 and CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David CAMPBELL, Thomas R. DIRAIMONDO,
Filed: 21 Oct 21
Utility
Multispecific Antibodies for Targeting CD28 and PD-L1 and Methods of Use Thereof
21 Dec 23
Provided herein are antibodies that selectively bind to CD28 and PD-L1, pharmaceutical compositions thereof, as well as nucleic acids, and methods of use, and methods for making and discovering the same.
David CAMPBELL, Thomas R. DIRAIMONDO
Filed: 29 Oct 21
Utility
Optimized Antibodies Targeting TROP2 and Uses Thereof
9 Nov 23
Disclosed herein are isolated polypeptides or polypeptide complexes that comprise a tumor-associated calcium signal transducer 2 (TROP2) binding domain that has been optimized for binding and kinetic properties.
David CAMPBELL, Thomas R. DIRAIMONDO
Filed: 8 May 23
Utility
Tumor Activated Multispecific Antibodies for Targeting CD28 and PD-L1 and Methods of Use Thereof
9 Nov 23
Provided herein are antibodies that selectively bind to CD28 and PD-L1, pharmaceutical compositions thereof, as well as nucleic acids, and methods of use, and methods for making and discovering the same.
David CAMPBELL, Thomas R. DIRAIMONDO
Filed: 8 May 23
Utility
Compositions and Methods Related to Tumor Activated Antibodies Targeting Psma and Effector Cell Antigens
2 Nov 23
Provided herein are multispecific antibodies that selectively bind to PSMA and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David CAMPBELL, Thomas R. DiRaimondo
Filed: 16 Nov 22
Utility
Modified Antibodies
31 Aug 23
Provided herein are modified antibodies, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David Campbell, Ramesh Bhatt, William J. Dower, Steven E. Cwirla, Blake M. Williams
Filed: 8 Dec 22
Utility
Compositions and Methods Relating to Tumor Activated T Cell Engagers
13 Jul 23
Provided herein are modified T cell engagers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO
Filed: 5 Jun 20
Utility
Tumor Activated T Cell Engagers and Methods of Use Thereof
13 Jul 23
Provided herein are modified T cell engagers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO
Filed: 5 Jun 20
Utility
Cleavable Linker Compositions and Methods
11 May 23
Provided herein are cleavable linkers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David CAMPBELL, Thomas R. DiRaimondo
Filed: 24 Oct 22
Utility
Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens
17 Jan 23
Provided herein are multispecific antibodies that selectively bind to PSMA and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David Campbell, Thomas R. DiRaimondo
Filed: 7 Dec 21
Utility
Cleavable linker compositions and methods
29 Nov 22
Provided herein are cleavable linkers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David Campbell, Thomas R. DiRaimondo
Filed: 10 Aug 21
Utility
Compositions and Methods Related to Tumor Activated Antibodies Targeting Psma and Effector Cell Antigens
9 Jun 22
Provided herein are multispecific antibodies that selectively bind to PSMA and effector cell antigens such as CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David CAMPBELL, Thomas R. DiRaimondo
Filed: 7 Dec 21
Utility
Cleavable Linker Compositions and Methods
17 Feb 22
Provided herein are cleavable linkers, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David CAMPBELL, Thomas R. DiRaimondo
Filed: 10 Aug 21
Utility
Inhibitory T Cell Receptor Peptides and Discovery Methods
2 Dec 21
Disclosed herein are methods of inhibiting an interaction of a T cell receptor with a peptide-major histocompatibility complex comprising administering inhibitory peptides that bind to the T cell receptor without the aid of a major histocompatibility complex to inhibit the interaction, and methods of identifying the inhibitory peptides.
David CAMPBELL, Ramesh BHATT, Thomas DIRAIMONDO
Filed: 31 Jul 19
Utility
Modified T Cell Receptors
22 Apr 21
Provided herein are modified T cell receptors (TCRs), pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO, Steven E. CWIRLA, Blake M. WILLIAMS, Praechompoo PONGTORNPIPAT, William J. DOWER
Filed: 6 Dec 18
Utility
Modified Bispecific T Cell Receptors
9 Dec 20
Provided herein are modified T cell receptors (TCRs), pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
David CAMPBELL, Ramesh BHATT, Thomas R. DIRAIMONDO, Steven E. CWIRLA, Blake M. WILLIAMS, Praechompoo PONGTORNPIPAT, William J. DOWER
Filed: 5 Dec 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first